AU2003215336A1 - Compositions and formulations of 9- nitrocamptothecin polymorphs and methods of use thereof - Google Patents

Compositions and formulations of 9- nitrocamptothecin polymorphs and methods of use thereof Download PDF

Info

Publication number
AU2003215336A1
AU2003215336A1 AU2003215336A AU2003215336A AU2003215336A1 AU 2003215336 A1 AU2003215336 A1 AU 2003215336A1 AU 2003215336 A AU2003215336 A AU 2003215336A AU 2003215336 A AU2003215336 A AU 2003215336A AU 2003215336 A1 AU2003215336 A1 AU 2003215336A1
Authority
AU
Australia
Prior art keywords
nitrocamptothecin
characterizable
polymorph
polymorphic form
exotherm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003215336A
Other languages
English (en)
Inventor
Ashok Y Gore
Sanjeev Redkar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astex Pharmaceuticals Inc
Original Assignee
Supergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supergen Inc filed Critical Supergen Inc
Publication of AU2003215336A1 publication Critical patent/AU2003215336A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
AU2003215336A 2002-02-21 2003-02-19 Compositions and formulations of 9- nitrocamptothecin polymorphs and methods of use thereof Abandoned AU2003215336A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US10/081,745 US6482830B1 (en) 2002-02-21 2002-02-21 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
US10/081,998 US6492379B1 (en) 2002-02-21 2002-02-21 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
US10/082,003 2002-02-21
US10/082,003 US7049322B2 (en) 2002-02-21 2002-02-21 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
US10/080,530 2002-02-21
US10/081,998 2002-02-21
US10/081,991 2002-02-21
US10/081,745 2002-02-21
US10/081,991 US6756381B2 (en) 2002-02-21 2002-02-21 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereof
US10/080,530 US7071202B2 (en) 2002-02-21 2002-02-21 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
US10/267,909 US6696458B2 (en) 2002-02-21 2002-10-08 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereof
US10/267,909 2002-10-08
PCT/US2003/005118 WO2003072027A2 (en) 2002-02-21 2003-02-19 Compositions and formulations of 9- nitrocamptothecin polymorphs and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2003215336A1 true AU2003215336A1 (en) 2003-09-09

Family

ID=27767969

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003215336A Abandoned AU2003215336A1 (en) 2002-02-21 2003-02-19 Compositions and formulations of 9- nitrocamptothecin polymorphs and methods of use thereof

Country Status (6)

Country Link
US (7) US6482830B1 (enExample)
EP (1) EP1476159A4 (enExample)
JP (1) JP2005520819A (enExample)
AU (1) AU2003215336A1 (enExample)
CA (1) CA2476630A1 (enExample)
WO (1) WO2003072027A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002068398A1 (en) * 2001-02-27 2002-09-06 Teva Pharmaceutical Industries Ltd. New crystal forms of lamotrigine and processes for their preparations
US8133501B2 (en) 2002-02-08 2012-03-13 Boston Scientific Scimed, Inc. Implantable or insertable medical devices for controlled drug delivery
US6887270B2 (en) 2002-02-08 2005-05-03 Boston Scientific Scimed, Inc. Implantable or insertable medical device resistant to microbial growth and biofilm formation
US7993390B2 (en) * 2002-02-08 2011-08-09 Boston Scientific Scimed, Inc. Implantable or insertable medical device resistant to microbial growth and biofilm formation
US8685427B2 (en) 2002-07-31 2014-04-01 Boston Scientific Scimed, Inc. Controlled drug delivery
US6482830B1 (en) * 2002-02-21 2002-11-19 Supergen, Inc. Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
CA2483103A1 (en) * 2002-04-23 2003-11-06 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing lamotrigine particles of defined morphology
US8920826B2 (en) 2002-07-31 2014-12-30 Boston Scientific Scimed, Inc. Medical imaging reference devices
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
EP1699435A4 (en) * 2003-09-18 2009-05-20 Norton Healthcare Ltd PARTICLE
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
AR046579A1 (es) * 2003-11-12 2005-12-14 Smithkline Beecham Corp Compuesto cristalino de topotecan, composicion farmaceutica que lo comprende, procedimiento para prepararlo y su uso para preparar dicha composicion farmaceutica
CN1324032C (zh) * 2004-01-07 2007-07-04 重庆医药工业研究院有限责任公司 一种新的9－硝基喜树碱晶型和药物组合物
US7371906B2 (en) * 2004-08-24 2008-05-13 Eastman Kodak Company Process for photo-oxidative stability improvements
ITFI20050087A1 (it) * 2005-05-02 2006-11-03 Perini Fabio Spa Metodo e dispositivo per produrre rotoli di materiale nastriforme con una fasciatura esterna
IL168603A (en) * 2005-05-16 2011-05-31 Resdevco Res And Dev Co Pharmaceutical or cosmetic composition for the prevention and treatment of irritation of mucous cells or skin cells
US20070123539A1 (en) * 2005-10-20 2007-05-31 University Of South Florida Treatment of Restenosis and Stenosis with Dasatinib
US20070099992A1 (en) * 2005-11-03 2007-05-03 Kane Lynn C N Direct application of vitamin C to the lung tissue and respiratory passages by use of an asthma medication-type inhaler or similar inhaler
US20100038816A1 (en) * 2006-08-16 2010-02-18 Novartis Ag Method of making solid dispersions of highly crystalline therapeutic compounds
US8307341B2 (en) * 2007-04-25 2012-11-06 International Business Machines Corporation Generating customized documentation for a software product
CN103130814B (zh) * 2011-11-25 2016-03-09 上海医药工业研究院 两种9-硝基喜树碱新晶型及其制备方法
GB201700555D0 (en) 2017-01-12 2017-03-01 Peptinnovate Ltd Method for the treatment of a relapsing-remitting condition
US12331088B2 (en) 2017-01-12 2025-06-17 Revolo Biotherapeutics Limited Method for the treatment of a relapsing-remitting condition
US12358957B2 (en) 2017-01-12 2025-07-15 Revolo Biotherapeutics Limited Method for the acute treatment of atopic dermatitis and allergic skin hypersensitivity

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3700819A (en) 1970-12-07 1972-10-24 Bell Telephone Labor Inc Time division switching system with time slot interchange
US3883847A (en) 1974-03-28 1975-05-13 Bell Telephone Labor Inc Uniform decoding of minimum-redundancy codes
JPH0763151B2 (ja) 1985-09-18 1995-07-05 日本電気株式会社 可変長符号複号化回路
US4894456A (en) * 1987-03-31 1990-01-16 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US4981968A (en) * 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US5552154A (en) * 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
US5225404A (en) * 1989-11-06 1993-07-06 New York University Methods of treating colon tumors with tumor-inhibiting camptothecin compounds
US5162532A (en) * 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
US5559235A (en) * 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
JPH05152973A (ja) 1991-11-28 1993-06-18 Fujitsu Ltd 可変長符号復号器
JPH05173844A (ja) 1991-12-19 1993-07-13 Nec Corp コーディングミス修正方式
JP2842094B2 (ja) 1992-10-13 1998-12-24 日本電気株式会社 ハフマン復号回路
GB9319944D0 (en) * 1993-09-28 1993-11-17 Erba Carlo Spa Process for the preparation of 9-amino camptothecin
US5731316A (en) * 1996-01-30 1998-03-24 The Stehlin Foundation For Cancer Research Derivatives of camptothecin and methods of treating cancer using these derivatives
US6096336A (en) * 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
JPH09307456A (ja) 1996-05-09 1997-11-28 Matsushita Electric Ind Co Ltd 可変長符号復号装置及び方法
US5922877A (en) * 1997-08-05 1999-07-13 The Stehlin Foundation For Cancer Research Methods of preparing and purifying 9-nitro-20-camptothecin
JPH11168391A (ja) 1997-12-04 1999-06-22 Matsushita Electric Ind Co Ltd 復号装置
US6291676B1 (en) 1999-03-03 2001-09-18 University Of Kentucky Research Foundation Water-soluble derivatives of camptothecin/homocamptothecin
US6288072B1 (en) * 1999-12-29 2001-09-11 Monroe E. Wall Camptothecin β-alanine esters with topoisomerase I inhibition
AU2001240024A1 (en) * 2000-03-31 2001-10-15 Supergen, Inc. Camptothecin complexes
US6482830B1 (en) * 2002-02-21 2002-11-19 Supergen, Inc. Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor

Also Published As

Publication number Publication date
US20030166671A1 (en) 2003-09-04
WO2003072027A2 (en) 2003-09-04
WO2003072027A3 (en) 2004-06-10
US20060217407A1 (en) 2006-09-28
JP2005520819A (ja) 2005-07-14
US6482830B1 (en) 2002-11-19
US7049322B2 (en) 2006-05-23
US20030181476A1 (en) 2003-09-25
US6696458B2 (en) 2004-02-24
US7071202B2 (en) 2006-07-04
US6492379B1 (en) 2002-12-10
US20030181477A1 (en) 2003-09-25
EP1476159A4 (en) 2006-03-01
US20030176453A1 (en) 2003-09-18
US6756381B2 (en) 2004-06-29
CA2476630A1 (en) 2003-09-04
EP1476159A2 (en) 2004-11-17

Similar Documents

Publication Publication Date Title
US6696458B2 (en) Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereof
AU2011200539A1 (en) Compositions and formulations of decitabine polymorphs and methods of use thereof
EP2094700B1 (en) Crystalline monotosylate salt of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile
AU2011327113B2 (en) Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same
TWI461429B (zh) 二胺衍生物的結晶及其製造方法
EP1487840B1 (en) Crystalline polymorphic form of irinotecan hydrochloride
US20100286254A1 (en) Crystalline forms of dmxaa sodium salt
EP4027999B1 (en) Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
EP1603919B1 (en) 7-imino derivatives of camptothecin having antitumor activity
BRPI0714672B1 (pt) derivados de camptotecina, composição farmacêutica contendo os mesmos e seu uso

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application